HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SPRO
Spero Therapeutics, Inc.
There isn't enough reported data to score SPRO yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SPRO Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Weak | |
| Strong |
SPRO's balance sheet is currently strong, and its profitability is stable, but its revenue and cash flow are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SPRO PE Valuation
SPRO has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SPRO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect SPRO's losses to shrink, with revenue holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
SPRO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.49 | +$0.30 |
| Q2 2026 | $0.14 | +$1.12 |
| Q1 2026 | $0.27 | +$1.55 |
| Q4 2025 | $0.15 | +$1.42 |
| Q3 2025 | -$0.79 | -1088% |
| Q2 2025 | -$0.98 | -388% |
| Q1 2025 | -$1.28 | -391% |
| Q4 2024 | -$1.27 | -395% |
SPRO is still losing money, but far less than before: $0.49 per share over the past year, against $4.33 at its worst in mid-2020.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over SPRO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
SPRO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $258K | -96% |
| Q4 2025 | $41.3M | +175% |
| Q3 2025 | $5.4M | -60% |
| Q2 2025 | $14.2M | +39% |
| Q1 2025 | $5.9M | -37% |
| Q4 2024 | $15M | -80% |
| Q3 2024 | $13.5M | -47% |
| Q2 2024 | $10.2M | +275% |
SPRO's revenue fell from its 2023 peak and has held roughly level since: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -2922% | -2671 points |
| Q4 2025 | 76% | +221 points |
| Q3 2025 | -145% | -7.4 points |
| Q2 2025 | -17% | +170 points |
| Q1 2025 | -251% | -100 points |
| Q4 2024 | -144% | -213 points |
| Q3 2024 | -138% | -130 points |
| Q2 2024 | -187% | +288 points |
SPRO's operating margin was −2922% last quarter, down 2671 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SPRO on cash generation, producing positive trailing cash flow while its opponent burns cash.
SPRO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$42.6M | -345% |
| Q2 2026 | -$5.4M | +$12.3M |
| Q1 2026 | $15.9M | +$19.9M |
| Q4 2025 | -$8.4M | +$15.1M |
| Q3 2025 | $17.4M | +37% |
| Q2 2025 | -$17.7M | +$1.1M |
| Q1 2025 | -$4M | -167% |
| Q4 2024 | -$23.4M | -$5.9M |
SPRO has burned cash in most quarters: −$40M over the past year, against −$28M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SPRO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SPRO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +261K shares |
| 1 year | +3.5% | +1.9M shares |
| 3 years | +10% | +5.5M shares |
| 5 years | +96% | +28.6M shares |
| Available history | +206% | +39.2M shares |
SPRO has 58M diluted shares, up 3.5% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SPRO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2024 | -4.1x | Net Cash |
| Q1 2024 | -3.7x | Net Cash |
| Q4 2023 | -3.5x | Net Cash |
SPRO has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SPRO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.4 | Oversold |
| Stochastic | 9.2 | Oversold |
SPRO's weekly RSI is 26 (oversold) and its Stochastic is 9 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SPRO PE vs Healthcare Sector
| Metric | SPRO | Sector median | Relative |
|---|---|---|---|
| PE | 7.4x | 26x | 72% below |
| PE % | 55 | 29 | 26 pts above |
SPRO has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SPRO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.11 | 9.9% below |
| 20 week MA | $1.28 | 22% below |
| 50 week MA | $2.00 | 50% below |
| 100 week MA | $1.81 | 45% below |
| 200 week MA | $1.63 | 39% below |
SPRO is in a downtrend: it's below all five of its weekly moving averages, and 39% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over SPRO on returns for 2026, with the stronger performance.
SPRO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.4 | $22.0 | +111% |
| 2021 | $22.0 | $14.0 | -36% |
| 2022 | $14.0 | $1.59 | -89% |
| 2023 | $1.59 | $1.47 | -7.5% |
| 2024 | $1.47 | $1.03 | -30% |
| 2025 | $1.03 | $2.32 | +125% |
| 2026 YTD | $2.32 | $1.00 | -57% |
SPRO's yearly returns have swung widely, from +125% in 2025 to −89% in 2022. It's down 57% so far in 2026.